文献速递糖尿病

TOPMed插补在发现拉丁裔富集且与2型糖尿病相关的罕见变异中的效力

The power of TOPMed imputation for the discovery of Latino-enriched rare variants associated with type 2 diabetes.
PubMed 文献 · Diabetologia · 2023-05-06

研究评估TOPMed插补面板在六个拉丁裔队列中的表现,并对8150例2型糖尿病和10735例对照进行全基因组关联分析荟萃分析,发现26个全基因组显著信号,包括一个新变异(次等位基因频率1.7%;OR 1.37,p=3.4×10-9)。拉丁裔定制多基因评分在目标数据集中解释高达7.6%的2型糖尿病风险方差。

要点

  • TOPMed插补较1000G插补改善了罕见和低频变异的识别。
  • 拉丁裔2型糖尿病GWAS荟萃分析发现26个全基因组显著信号。
  • 拉丁裔定制多基因评分解释高达7.6%的2型糖尿病风险方差。

核心结论

  • TOPMed插补有助于在未被充分研究的人群中识别低频变异,发现新的疾病关联并改善多基因评分。

研究设计与样本

  • 利用六个拉丁裔队列的基因分型芯片和全外显子组序列数据评估TOPMed插补性能。
  • 在8150例2型糖尿病患者和10735例对照中进行拉丁裔2型糖尿病GWAS荟萃分析。
  • 在另外六个队列中重复验证,包括All of Us队列的全基因组序列数据。

主要发现

  • 与1000G插补相比,TOPMed面板改善了罕见和低频变异的识别。
  • 识别出26个全基因组显著信号,包括一个新变异(次等位基因频率1.7%;OR 1.37,p=3.4×10-9)。
  • 基于本研究数据及东亚和欧洲人群GWAS数据构建的拉丁裔定制多基因评分在拉丁裔目标数据集中解释高达7.6%的2型糖尿病风险方差。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS/HYPOTHESIS: The Latino population has been systematically underrepresented in large-scale genetic analyses, and previous studies have relied on the imputation of ungenotyped variants based on the 1000 Genomes (1000G) imputation panel, which results in suboptimal capture of low-frequency or Latino-enriched variants. The National Heart, Lung, and Blood Institute (NHLBI) Trans-Omics for Precision Medicine (TOPMed) released the largest multi-ancestry genotype reference panel representing a unique opportunity to analyse rare genetic variations in the Latino population. We hypothesise that a more comprehensive analysis of low/rare variation using the TOPMed panel would improve our knowledge of the genetics of type 2 diabetes in the Latino population. METHODS: We evaluated the TOPMed imputation performance using genotyping array and whole-exome sequence data in six Latino cohorts. To evaluate the ability of TOPMed imputation to increase the number of identified loci, we performed a Latino type 2 diabetes genome-wide association study (GWAS) meta-analysis in 8150 individuals with type 2 diabetes and 10,735 control individuals and replicated the results in six additional cohorts including whole-genome sequence data from the All of Us cohort. RESULTS: Compared with imputation with 1000G, the TOPMed panel improved the identification of rare and low-frequency variants. We identified 26 genome-wide significant signals including a novel variant (minor allele frequency 1.7%; OR 1.37, p=3.4 × 10-9). A Latino-tailored polygenic score constructed from our data and GWAS data from East Asian and European populations improved the prediction accuracy in a Latino target dataset, explaining up to 7.6% of the type 2 diabetes risk variance. CONCLUSIONS/INTERPRETATION: Our results demonstrate the utility of TOPMed imputation for identifying low-frequency variants in understudied populations, leading to the discovery of novel disease associations and the improvement of polygenic scores. DATA AVAILABILITY: Full summary statistics are available through the Common Metabolic Diseases Knowledge Portal ( https://t2d.hugeamp.org/downloads.html ) and through the GWAS catalog ( https://www.ebi.ac.uk/gwas/ , accession ID: GCST90255648). Polygenic score (PS) weights for each ancestry are available via the PGS catalog ( https://www.pgscatalog.org , publication ID: PGP000445, scores IDs: PGS003443, PGS003444 and PGS003445).

来源:Diabetologia,查看原文。版权归原作者所有。

引用

  1. Huerta-Chagoya A, Schroeder P, Mandla R, et al. The power of TOPMed imputation for the discovery of Latino-enriched rare variants associated with type 2 diabetes. Diabetologia. 2023. PMID: 37148359. doi:10.1007/s00125-023-05912-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。